MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ
3.620
-0.160
-4.23%
After Hours: 3.620 0 0.00% 16:10 12/12 EST
OPEN
3.700
PREV CLOSE
3.780
HIGH
3.850
LOW
3.600
VOLUME
50.42K
TURNOVER
--
52 WEEK HIGH
41.70
52 WEEK LOW
2.710
MARKET CAP
15.35M
P/E (TTM)
-0.3359
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CLRB last week (1201-1205)?
Weekly Report · 5d ago
Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies
Reuters · 12/05 22:49
Weekly Report: what happened at CLRB last week (1124-1128)?
Weekly Report · 12/01 10:19
Weekly Report: what happened at CLRB last week (1117-1121)?
Weekly Report · 11/24 10:24
Weekly Report: what happened at CLRB last week (1110-1114)?
Weekly Report · 11/17 10:24
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI) and Cellectar Biosciences (CLRB)
TipRanks · 11/14 13:00
Cellectar Biosciences Reports Q3 2025 Financial Progress
TipRanks · 11/14 04:32
Cellectar Biosciences: Positive Outlook Amidst Challenges
TipRanks · 11/14 00:40
More
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.

Webull offers Cellectar Biosciences Inc stock information, including NASDAQ: CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.